Cerebrospinal fluid concentrations of antituberculosis agents in adults and children
- PMID: 20709598
- DOI: 10.1016/j.tube.2010.07.002
Cerebrospinal fluid concentrations of antituberculosis agents in adults and children
Abstract
Tuberculous meningitis (TBM) causes a devastating morbidity and mortality in adults and children. Even in patients presenting at an early stage of disease, deterioration may occur despite apparently adequate therapy. The literature relating to cerebrospinal fluid penetration of antituberculosis agents is reviewed. Amongst the essential antituberculosis agents isoniazid has the best CSF pharmacokinetics reaching peak concentrations (C(max)) only slightly less than in blood. Pyrazinamide also has good CSF penetration and in children receiving dosages of 40 mg/kg the CSF C(max) exceeds the proposed minimal inhibitory concentration of 20 μg/ml. Streptomycin other aminoglycosides and ethambutol have poor CSF penetration and cannot be agents of first choice for TBM treatment. Rifampicin at dosages used in adults seldom reaches CSF concentrations exceeding MIC, but does so more frequently in children when dosages of up to 20 mg/kg are used. The non-essential agents ethionamide, the fluoroquinolones, with the exception of ciprofloxacin, and cycloserine (terizadone) have relatively good CSF penetration and are recommended for TBM treatment. The dosages of the essential agents recommended for the treatment of TBM in children are INH 10 mg/kg (range 6-15 mg/kg bodyweight), rifampicin 15 mg/kg (range 10-20 mg/kg), pyrazinamide 35 mg/kg (range 30-40 mg/kg), ethambutol 20 mg/kg (range 15-25 mg/kg) and streptomycin 15 mg/kg (range 12-18 mg/kg). Amongst second-line agents ofloxacin, levofloxacin and moxifloxacin should be used in dosages of 15-20 mg/kg, ethionamide 20 mg/kg in a single dose, if tolerated, and for cycloserine (terizadone) 15 mg/kg. Antituberculous chemotherapy should be started as soon as the diagnosis of TBM is considered.
Copyright © 2010. Published by Elsevier Ltd.
Similar articles
-
The chemotherapy of tuberculous meningitis in children and adults.Tuberculosis (Edinb). 2010 Nov;90(6):375-92. doi: 10.1016/j.tube.2010.07.003. Tuberculosis (Edinb). 2010. PMID: 20810322 Review.
-
Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0009925. doi: 10.1128/aac.00099-25. Epub 2025 Jul 1. Antimicrob Agents Chemother. 2025. PMID: 40590723 Free PMC article. Clinical Trial.
-
Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.Arch Dis Child. 2022 Jan;107(1):70-77. doi: 10.1136/archdischild-2020-321426. Epub 2021 Jun 28. Arch Dis Child. 2022. PMID: 34183327 Free PMC article.
-
Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.BMC Infect Dis. 2016 Apr 2;16:144. doi: 10.1186/s12879-016-1470-x. BMC Infect Dis. 2016. PMID: 27039088 Free PMC article.
-
Pyrazinamide pharmacokinetics and efficacy in adults and children.Tuberculosis (Edinb). 2012 Jan;92(1):1-8. doi: 10.1016/j.tube.2011.05.006. Epub 2011 Jul 26. Tuberculosis (Edinb). 2012. PMID: 21795116 Review.
Cited by
-
Pharmacokinetics of Antimicrobials in Children with Emphasis on Challenges Faced by Low and Middle Income Countries, a Clinical Review.Antibiotics (Basel). 2022 Dec 22;12(1):17. doi: 10.3390/antibiotics12010017. Antibiotics (Basel). 2022. PMID: 36671218 Free PMC article. Review.
-
Mycobacterium tuberculosis exploits the PPM1A signaling pathway to block host macrophage apoptosis.Sci Rep. 2017 Feb 8;7:42101. doi: 10.1038/srep42101. Sci Rep. 2017. PMID: 28176854 Free PMC article.
-
Cerebrospinal fluid matrix metalloproteinase 9 levels, blood-brain barrier permeability, and treatment outcome in tuberculous meningitis.PLoS One. 2017 Jul 12;12(7):e0181262. doi: 10.1371/journal.pone.0181262. eCollection 2017. PLoS One. 2017. PMID: 28704492 Free PMC article. Clinical Trial.
-
The current global situation for tuberculous meningitis: epidemiology, diagnostics, treatment and outcomes.Wellcome Open Res. 2019 Nov 5;4:167. doi: 10.12688/wellcomeopenres.15535.1. eCollection 2019. Wellcome Open Res. 2019. PMID: 32118118 Free PMC article. Review.
-
Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.Int J Infect Dis. 2021 Apr;105:688-694. doi: 10.1016/j.ijid.2021.03.001. Epub 2021 Mar 5. Int J Infect Dis. 2021. PMID: 33684562 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources